Core Viewpoint - Yuyuan Pharmaceutical's subsidiary has received FDA approval for clinical trials of YKYY018, a novel aerosol inhalation drug aimed at preventing and treating respiratory syncytial virus (RSV) infections, addressing a significant unmet medical need in the market [1] Company Summary - Yuyuan Pharmaceutical's subsidiary, Beijing Yuyuan Kecai Pharmaceutical Technology Co., Ltd., has developed YKYY018, an original membrane fusion inhibitor drug utilizing a full-process AI platform [1] - The drug is positioned to fill a gap in the market as there are currently no approved treatments for RSV infections globally [1] Industry Summary - The clinical treatment field for RSV infections shows a significant and urgent unmet demand, highlighting the potential market opportunity for new therapeutic options [1]

Core Viewpoint - YKYY018 aerosol inhalation agent developed by the company has received FDA approval for clinical trials aimed at preventing and treating respiratory syncytial virus (RSV) infections [1] Company Summary - The company’s wholly-owned subsidiary, Beijing YKANG Kechuang Pharmaceutical Technology Co., Ltd., has obtained the FDA's Study May Proceed Letter for YKYY018 [1] - YKYY018 is an internationally original membrane fusion inhibitor drug developed using the company's AI platform, specifically targeting RSV infections [1] - The product has a novel mechanism of action, binding specifically to the HR1 region of the F protein of RSV, inhibiting the formation of the 6-HB structure, and blocking the fusion process between the virus and host cells [1] - The company holds core patent rights for YKYY018 and possesses global exclusive rights to the product [1]